BLM Gene Variant rs121907993: Understanding Bloom Syndrome Carriers
The genetic variant rs121907993 is a specific change within the BLM gene, classified as a pathogenic stop-gain mutation. It is most notably associated with an increased risk of being a carrier for Bloom syndrome, a rare genetic disorder characterized by genomic instability.
What each genotype means
Typical BLM gene profile
This genotype represents the common, non-pathogenic sequence for this specific location in the BLM gene. Individuals with this result do not carry the specific stop-gain mutation associated with Bloom syndrome at this site. This result does not rule out the presence of other, different mutations in the BLM gene that could be associated with clinical conditions.
This is the most common genotype observed in the general population across all ancestries.
Bloom syndrome carrier status
This genotype indicates you are a carrier of the p.Gln672Ter (Q672X) pathogenic variant in the BLM gene. Bloom syndrome is an autosomal recessive condition, meaning carriers typically do not exhibit symptoms, but should discuss reproductive risks and family planning with a genetic counselor or healthcare provider. Because this variant is associated with increased cancer risk in some contexts, you may wish to discuss proactive health management with your physician.
This genotype is found in approximately 1 in 100 individuals of Ashkenazi Jewish descent.
Potential Bloom syndrome genotype
This genotype indicates the presence of two copies of the p.Gln672Ter (Q672X) pathogenic variant. Bloom syndrome is a rare autosomal recessive disorder characterized by chromosomal instability, growth deficiency, and increased cancer risk. If this result was unexpected, it is essential to consult with a medical geneticist or clinical specialist to discuss diagnostic confirmation and appropriate clinical management.
This genotype is extremely rare in the general population.
Understanding rs121907993
The genetic variant rs121907993 is a specific change within the BLM gene, classified as a pathogenic stop-gain mutation. It is most notably associated with an increased risk of being a carrier for Bloom syndrome, a rare genetic disorder characterized by genomic instability. This variant is a single nucleotide polymorphism that results in a premature stop codon, which is a critical alteration in the genetic code. Because it is a well-documented pathogenic variant, it is frequently included in carrier screening panels, particularly for populations where the mutation is known to be more prevalent. Understanding this variant requires looking at how it disrupts the normal production of proteins necessary for DNA repair. While the presence of this variant is a significant finding in a clinical context, it is important to distinguish between being a carrier and being affected by the associated condition. The variant serves as a marker for potential reproductive risks rather than a diagnostic indicator of current health status for the individual carrying it.
The Role of the BLM Gene
The BLM gene provides instructions for producing a protein called the Bloom syndrome protein, which belongs to a family of enzymes known as RecQ helicases. These proteins are essential for maintaining the stability of a cell’s DNA. They act as caretakers of the genome, helping to repair damaged DNA and ensuring that genetic material is copied accurately during cell division. When the BLM gene is functioning correctly, it helps prevent chromosomal rearrangements that can lead to various health issues. However, if both copies of the gene are mutated, the resulting deficiency in the BLM protein leads to increased rates of chromosomal breakage and sister chromatid exchange. This genomic instability is the hallmark of Bloom syndrome, which can manifest as short stature, a characteristic facial rash, immune system deficiencies, and a significantly increased risk of developing various types of cancer at an early age. The protein's role in maintaining genomic integrity is vital for preventing the accumulation of mutations that could otherwise lead to cellular dysfunction.
Research and Evidence Strength
The evidence linking rs121907993 to Bloom syndrome is well-established in clinical genetics literature. According to databases like ClinVar, this variant is classified as pathogenic, meaning it is definitively associated with the development of Bloom syndrome when inherited in an autosomal recessive pattern. The mutation is a stop-gain or nonsense mutation, specifically p.Gln672Ter (or Q672X), which introduces a premature stop signal in the protein-coding sequence. This signal causes the cell to produce a truncated, non-functional version of the BLM protein. While the molecular mechanism is clearly understood, the evidence strength regarding the clinical outcomes for carriers—individuals who have only one copy of this mutation—is generally considered to be limited. Carriers are typically healthy and do not exhibit the symptoms of Bloom syndrome, though they remain important for genetic counseling purposes when considering reproductive planning. The classification of this variant as pathogenic is supported by extensive clinical observation and molecular studies confirming its impact on protein function.
Population Frequency and Distribution
This specific BLM variant is well-documented as a founder mutation within the Ashkenazi Jewish population. In this ancestral group, the carrier frequency is approximately 1 in 100. Outside of this population, the variant is extremely rare or virtually absent in global genetic datasets such as gnomAD. The high prevalence within this specific community is attributed to the founder effect, where a small group of ancestors possessed the mutation, and it was subsequently passed down through generations. Because it is highly ancestry-specific, individuals of Ashkenazi Jewish descent are more likely to encounter information regarding this variant during routine carrier screening. For other populations, the statistical likelihood of carrying this specific BLM mutation is significantly lower, highlighting the importance of considering ancestry when interpreting genetic testing results. Genetic databases continue to refine these frequency estimates as more diverse populations are sequenced, but the current data strongly emphasizes the concentration of this variant within the Ashkenazi Jewish community.
Managing Genetic Information
Understanding your status regarding rs121907993 is primarily relevant for reproductive health and family planning. Because Bloom syndrome follows an autosomal recessive inheritance pattern, an individual must inherit two copies of a pathogenic BLM mutation (one from each parent) to be affected by the disorder. If you are identified as a carrier, it simply means you possess one copy of the mutation and one functional copy of the gene; carriers do not typically experience health problems related to this variant. It is important to remember that genetic testing results should never be used to self-diagnose. If you receive a report indicating you are a carrier for this variant, the most productive step is to schedule an appointment with a certified genetic counselor. They can help interpret your results in the context of your personal and family medical history and provide guidance on the implications for your reproductive choices. Professional guidance ensures that the information is used appropriately to support informed decision-making regarding family health.
How common is this variant?
This variant is a founder mutation in the Ashkenazi Jewish population with a carrier frequency of approximately 1 in 100. It is extremely rare or absent in most other global populations.
Frequently asked questions
What is a carrier of Bloom syndrome?
A carrier of Bloom syndrome is an individual who has one mutated copy of the BLM gene and one normal copy. Carriers do not have Bloom syndrome themselves but can pass the mutation on to their children.
How is Bloom syndrome inherited?
Bloom syndrome is inherited in an autosomal recessive pattern. This means that for a child to be born with the condition, both parents must be carriers of a pathogenic BLM mutation and pass that mutation to their child.
Should I be tested for the BLM gene?
Genetic carrier screening is often recommended for individuals of Ashkenazi Jewish descent who are planning a pregnancy. You should discuss the benefits and limitations of this testing with your healthcare provider or a genetic counselor.
Does carrying this variant increase my cancer risk?
While individuals with two copies of the BLM mutation have a significantly increased risk of cancer, current research does not definitively establish a substantially elevated cancer risk for carriers who have only one copy. You should consult a medical professional for personalized risk assessment.
Sources & further reading
Educational information only, last refreshed 9/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs121907993?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29